Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients-Reference-Cited by-同舟云学术

Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients

Published:2011-05-19 Issue:1 Volume:118 Page:17-26
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Montemurro Filippo,Rossi Valentina,Cossu Rocca Maria,Martinello Rossella,Verri Elena,Redana Stefania,Adamoli Laura,Valabrega Giorgio,Sapino Anna,Aglietta Massimo,Viale Giuseppe,Goldhirsch Aron,Nolè Franco

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.26162/fullpdf

Reference31 articles.

1. Endocrine-responsive breast cancer and strategies for combating resistance;Ali;Nat Rev Cancer.,2002

2. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998;Li;J Clin Oncol.,2003

3. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009;Goldhirsch;Ann Oncol.,2009

4. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science.,1987

5. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer;Huang;J Clin Pathol.,2005

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Herbal compounds as promising therapeutic agents in precision medicine strategies for cancer: A systematic review;Journal of Integrative Medicine;2024-03

2. Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes;Breast Cancer;2024-01-17

3. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer;npj Breast Cancer;2023-05-31

4. Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer;Therapeutic Advances in Medical Oncology;2023-01

5. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes;JAMA Network Open;2022-12-15